Combinatrial treatment of anti-High Mobility Group Box-1 monoclonal antibody and epothilone B improves functional recovery after spinal cord contusion injury

Spinal cord injury (SCI) causes motor and sensory deficits is currently considered an incurable disease. We have previously reported that administration of anti-High Mobility Group Box-1 monoclonal antibody (anti-HMGB1 mAb) preserved lesion area improved locomotion recovery in mouse model SCI. In order to further enhance the recovery, we here examined combinatorial treatment anti-HMGB1 mAb epothilone B (Epo B), which has been promote axon regeneration. This significantly increased hindlimb movement compared with alone, although Epo alone failed increase functional recovery. These results are agreement was able decrease spreading surviving neuron numbers around lesion, whereas facilitated outgrowth only combination mAb, suggesting mAb-dependent tissue preservation necessary for exhibit its therapeutic effect. Taken together, can be as a novel clinically applicable strategy